Vynleads (VYND) 10-Q 19 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 19, 2020
Document And Entity Information
Entity Registrant Name	Vynleads, Inc.
Entity Central Index Key	0001745078
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Is Entity Emerging Growth Company?	true
Entity Shell Company	false
Elected Not To Use the Extended Transition Period	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		11,599,830
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Entity Incorporation State Country Name	DE
Entity File Number	333-227499

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current Assets:
Cash	$ 482	$ 63,395
Accounts receivable	635	635
Holdback Receivable from merchant, net of reserve for refunds of $513 and $3,111, respectively	30,269	45,284
Prepaid expenses and other current assets	20,206	3,081
Total current assets	51,592	112,395
Total assets	51,592	112,395
Current Liabilities:
Accounts payable and accrued expenses	234,414	172,757
Notes payable	92,074	75,000
Total current liabilities	326,488	247,757
Notes Payable, net of current	9,926
Total liabilities	336,414	247,757
Commitments and contingencies (See Note 6)
Stockholders' deficit:
Preferred stock; $0.0001 par value; 5,000,000 shares authorized, no shares issued and outstanding, respectively
Common stock; $0.0001 par value; 50,000,000 shares authorized; 11,599,830 shares and 11,399,830 shares issued and outstanding, respectively	1,160	1,140
Additional paid in capital	1,329,656	1,199,565
Accumulated deficit	(1,615,638)	(1,336,067)
Total stockholders' deficit	(284,822)	(135,362)
Total liabilities and stockholders' deficit	$ 51,592	$ 112,395

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Refunds	$ 513	$ 3,111
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, share issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	11,599,830	11,399,830
Common stock, shares outstanding	11,599,830	11,399,830

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue, net of refunds and chargebacks	$ 8,379	$ 141,406	$ 47,492	$ 357,474
Costs and Expenses:
Cost of revenue	13,104	52,366	52,866	144,856
Advertising	71	114,316	1,885	214,776
Selling, general and administrative expense	88,844	57,566	266,767	214,615
Total costs and expenses	102,019	224,248	321,518	574,247
Loss from operations	(93,640)	(82,842)	(274,026)	(216,773)
Other income			2,000
Interest expense	(2,063)	(577)	(5,990)	(2,023)
Net loss before provision for income taxes	(95,703)	(83,419)	(278,016)	(218,796)
Income tax expense			(1,555)
Net loss	$ (95,703)	$ (83,419)	$ (279,571)	$ (218,796)
Net loss per common share, basic and diluted	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Weighted average common shares outstanding, basic and diluted	11,491,498	11,399,830	11,520,252	11,399,830

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional paid-in capital [Member]	Accumulated deficit [Member]	Total
Balance at Dec. 31, 2018	$ 1,140	$ 1,082,552	$ (1,032,999)	$ 50,693
Balance, shares at Dec. 31, 2018	11,399,830
Stock-based compensation		143		143
Capital Contribution		20,654		20,654
Net Loss			(72,844)	(72,844)
Balance at Mar. 31, 2019	$ 1,140	1,103,349	(1,105,843)	(1,354)
Balance, shares at Mar. 31, 2019	11,399,830
Balance at Dec. 31, 2018	$ 1,140	1,082,552	(1,032,999)	50,693
Balance, shares at Dec. 31, 2018	11,399,830
Net Loss				(218,796)
Balance at Sep. 30, 2019	$ 1,140	1,168,467	(1,251,795)	(82,188)
Balance, shares at Sep. 30, 2019	11,399,830
Balance at Mar. 31, 2019	$ 1,140	1,103,349	(1,105,843)	(1,354)
Balance, shares at Mar. 31, 2019	11,399,830
Stock-based compensation		143		143
Capital Contribution		32,332		32,332
Net Loss			(62,533)	(62,533)
Balance at Jun. 30, 2019	$ 1,140	1,135,824	(1,168,376)	(31,412)
Balance, shares at Jun. 30, 2019	11,399,830
Stock-based compensation		143		143
Capital Contribution		32,500		32,500
Net Loss			(83,419)	(83,419)
Balance at Sep. 30, 2019	$ 1,140	1,168,467	(1,251,795)	(82,188)
Balance, shares at Sep. 30, 2019	11,399,830
Balance at Dec. 31, 2019	$ 1,140	1,199,565	(1,336,067)	$ (135,362)
Balance, shares at Dec. 31, 2019	11,399,830			11,399,830
Stock-based compensation		56		$ 56
Net Loss			(70,512)	(70,512)
Balance at Mar. 31, 2020	$ 1,140	1,199,621	(1,406,579)	(205,818)
Balance, shares at Mar. 31, 2020	11,399,830
Balance at Dec. 31, 2019	$ 1,140	1,199,565	(1,336,067)	$ (135,362)
Balance, shares at Dec. 31, 2019	11,399,830			11,399,830
Net Loss				$ (279,571)
Balance at Sep. 30, 2020	$ 1,160	1,329,656	(1,615,638)	$ (284,822)
Balance, shares at Sep. 30, 2020	11,599,830			11,599,830
Balance at Mar. 31, 2020	$ 1,140	1,199,621	(1,406,579)	$ (205,818)
Balance, shares at Mar. 31, 2020	11,399,830
Stock-based compensation		56		56
Issuance of Common Stock for Services	$ 20	44,980		45,000
Issuance of Common Stock for Services Shares	200,000
Net Loss			(113,356)	(113,356)
Balance at Jun. 30, 2020	$ 1,160	1,244,657	(1,519,935)	(274,118)
Balance, shares at Jun. 30, 2020	11,599,830
Stock-based compensation		56		56
Capital Contribution		84,943		84,943
Net Loss			(95,703)	(95,703)
Balance at Sep. 30, 2020	$ 1,160	$ 1,329,656	$ (1,615,638)	$ (284,822)
Balance, shares at Sep. 30, 2020	11,599,830			11,599,830

Condensed Statement of Cash Flo

Condensed Statement of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (279,571)	$ (218,796)
Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities
Stock-based compensation	28,293	429
Capital contribution from CEO's salary	84,943	85,486
Changes in assets and liabilities:
Changes in operating assets and liabilities and other, net	76,422	140,385
Net cash flows (used in) provided by operating activities	(89,913)	7,504
Cash flows from financing activities:
Proceeds from notes payable	27,000
Net cash flows provided by financing activities	27,000
Net increase (decrease) in cash	(62,913)	7,504
Cash at beginning of period	63,395	21,085
Cash at end of period	482	28,589
Supplemental disclosure of cash flow information:
Income taxes paid	1,555
Interest paid	4,460	$ 2,023
Supplemental for non-cash investing and financing activities:
Stock issued for prepaid consulting	$ 16,875

Business

Business	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business	1. Business Vynleads, Inc. (“Vynleads”) was incorporated as a Delaware corporation on July 15, 2015. We are a provider of health and wellness information principally targeted to people who have prediabetes or type 2 diabetes. We provide information to our customers who are seeking to make healthy choices by providing clear, generic blueprints, education, resources, and support. Our core product is our proprietary Lifestyle Blueprint, a digital guide that provides dietary recommendations for a very low calorie eight-week diet together with information focusing on what, how and how much a person eats, nutritional information and how a person’s body does and does not use food to enable our customers to continue leading a more successful lifestyle. We also offer nutritional supplements and monthly subscriptions to our proprietary newsletter which covers a wide variety of healthy living-related topics. Our corporate headquarters are located in Rock Hill, South Carolina.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2020
Going Concern
Going Concern	2. Going Concern Our condensed financial statements have been presented on the basis that we are a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since July 15, 2015, the date of our inception, we have experienced recurring operating losses and negative operating cash flows, and have financed our recent working capital requirements primarily through the issuance of debt and equity securities, as well as borrowings from related parties. During the three and nine months ended Despite our current sales, expense, cash flow projections, and aggregate cash and cash receivable from our merchant, net of reserve for refunds, of $30,269, we will require substantial funds to expand service and product offerings into additional areas, market and promote our services and product offerings; and develop and grow our infrastructure and corporate organization. Our capital requirements depend on numerous factors, including but not limited to our ability to generate sufficient revenues to pay our operating expenses. The COVID-19 pandemic has materially and adversely impacted the U.S. economy and financial markets, with legislative and regulatory responses including unprecedented monetary and fiscal policy actions across all sectors, and there is significant uncertainty as to timing of stabilization and recovery. The extent of the COVID-19 impacts will depend on future actions and outcomes, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the outbreak, the short-term and long-term economic impact of the outbreak (including the effect on advertising activity, consumer discretionary spending and our employees), and the actions taken to mitigate the impact of the virus, and the pace of economic and financial market recovery when the COVID-19 pandemic subsides, among others. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate adverse effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for the remainder of fiscal year 2020. Our ability to meet our current and projected obligations depends on our ability to generate sufficient sales and to control expenses and will require that we seek additional capital through private and/or public financing sources. There can be no assurances that we will achieve our forecasted financial results or that we will be able to raise additional capital to operate our business. Any such failure would have a material adverse impact on our liquidity and financial condition and could force us to curtail or discontinue operations entirely and could require us to file for protection under bankruptcy laws. These conditions raise substantial doubt as to our ability to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Accounting Principles The accompanying unaudited condensed financial statements (the “Financial Statements”) of Vynleads, Inc. (the “Company,” “we,” “us” or “our”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and, therefore, do not include all information and footnotes required by GAAP for complete financial statements. In our opinion, the Financial Statements contain all adjustments of a normal recurring nature necessary to present fairly our financial position as of September 30, 2020 and the results of our operations and cash flows for the nine months ended September 30, 2020 and 2019. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the full 2020 fiscal year. The Financial Statements should be read in conjunction with the audited financial statements for the Company and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “Form 10-K”). Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgement is involved in determining the valuation of our reserve for refunds, our holdback reserve, the fair value-based measurement of stock-based compensation, accruals and the estimated useful life of intangible assets. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements. Cash Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value. Holdback Receivable Holdback receivable includes a merchant holdback net of a reserve for refunds, which reserve is $513 and $3,111 as of September 30, 2020 and December 31, 2019, respectively. Revenue Recognition The Company accounts for revenue in accordance with Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition. We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Our percentages of revenue by type for the three and nine months ended September 30, 2020 and 2019 are as follows: Three months ended Nine months ended September 30, September 30, (Unaudited) (Unaudited) 2020 2019 2020 2019 Internet content subscriptions 10.8 % 51.6 % 7.7 % 53.6 % Nutritional supplements 89.3 % 48.4 % 92.3 % 46.4 % Shipping and Handling Costs We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue. Advertising Costs Advertising costs for the three months ended September 30, 2020 and 2019 were $71 and $114,316, respectively. Advertising costs for the nine months ended September 30, 2020 and 2019 were $1,885 and $214,776, respectively. Advertising costs are expensed as incurred or at the first time the advertising activity takes place. Loss Per Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 585,766 shares for the nine months ended September 30, 2020 and 2019. Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense. Stock-Based Compensation Stock-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. The valuation of employee stock options is an inherently subjective process, since market values are generally not available for long-term, non-transferable employee stock options. Accordingly, the Black-Scholes option pricing model is utilized to derive an estimated fair value. The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value: · the stock option exercise price; · the expected term of the option; · the grant date price of our common stock, which is issuable upon exercise of the option; · the expected volatility of our common stock; · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and · the risk-free interest rate for the expected option term. Expected Dividends. Expected Volatility. Risk-Free Interest Rate. Expected Term. Stock Option Exercise Price and Grant Date Price of Common Stock. We are required to estimate the level of award forfeitures expected to occur and record compensation expense only for those awards that are ultimately expected to vest. This requirement applies to all awards that are not yet vested. Due to the limited number of unvested options outstanding, the majority of which are held by executives and members of our Board of Directors, we have estimated a zero forfeiture rate. We will revisit this assumption periodically and as changes in the composition of the option pool dictate. Fair Value of Financial Instruments We follow Accounting Standards Codification 820-10 (“ASC 820-10”), “Fair Value Measurements and Disclosures,” for fair value measurements. ASC 820-10 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value, which focuses on an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurement based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below: Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price. Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments. Level 3 - Pricing inputs are unobservable for the investment, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Level 3 includes investments that are supported by little or no market activity. The carrying amounts of our cash, holdback receivable, prepaid expenses, accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of September 30, 2020 and December 31, 2019. Recent Accounting Pronouncements We have evaluated all issued but not yet effective accounting pronouncements and determined that, other than the following, they are either immaterial or not relevant to us. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 provide for simplified accounting to several income tax situations and removal of certain accounting exceptions. The ASU is effective for annual reporting periods beginning after December 15, 2020, including interim periods within those periods. We do not expect the impact of the adoption of ASU 2019-12 to have a material effect on the Company's results of operations, cash flows or financial condition.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	4. Related Party Transactions During the three months ended September 30, 2020 and 2019 we paid Mr. Bezusov $0 in consulting fees. During the nine months ended September 30, 2020 and 2019 we paid Mr. Bezusov $2,000 and $0, respectively, in consulting fees pursuant to a verbal agreement with him. We are not a party to an employment agreement with Mr. Bezusov and the compensation he is paid for his services is determined by the board of directors. On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. Mr. Mannine’s compensation includes a grant of 10 year options to purchase 100,000 shares of our common stock at an exercise price of $0.225 per share, which vested upon the effectiveness of the registration statement on December 7, 2018. On September 21, 2020, Mr. Mannine voluntarily agreed to cancel the employment agreement and waive all cash due and any related accruals. The salary forgiven for the nine months ended September 30, 2020 and 2019 of $84,943 and $85,486 is treated as in-kind contribution of service and reflected as contributed capital in the financial statements (See Note 8). On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2019, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed in May 2020. As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including: · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG; · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG; · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG. In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable On November 18, 2019, the Company executed a note payable to an individual in the amount of $50,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. On May 14, 2020, $1,250 of accrued interest was paid. Accrued interest on September 30, 2020 and December 31, 2019 is $894 and $295, respectively. This note is currently in default. On November 18, 2019, the Company executed a note payable to an individual in the amount of $25,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first. Accrued interest on September 30, 2020 and December 31, 2019 is $1,072 and $140, respectively. This note is currently in default. On May 5, 2020, the Company received loan proceeds in the amount of $27,000 from Bank of America (the “Lender”) under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act), provides for loans to qualifying business for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loan matures on April 20, 2022 and bears an interest rate of 1.00% fixed per annum, payable monthly commencing on October 20, 2020. The loan is forgivable if the proceeds are used for eligible purposes. The Company intends to use the entire loan amount for qualifying expenses. On April 14, 2020, the Company received a grant in the amount of $2,000 which does not have to be repaid from the SBA under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the business. The amount is included in “other income” in our condensed statement of operations.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Employment Agreement On June 14, 2018, we entered into an employment agreement with Mr. Mannine pursuant to which he was engaged to serve as our Chief Executive Officer. The initial term of the agreement expires in June 2023, subject to successive automatic one- year renewals unless a non-renewal notice is received by either party at least 90 days prior to the expiration of the then current renewal term. Mr. Mannine’s compensation includes: · an annual base salary of $130,000, subject to an annual review with an increase of at least 5% per annum as determined by the board of directors; · an annual bonus as determined by the board of directors; · a grant of 10-year options to purchase 100,000 shares of our common stock at an exercise price of $0.225 per share which vest upon the effectiveness of a registration statement to be filed with the Securities and Exchange Commission; · participation in all benefit plans we may offer our employees; and · 20 paid vacation days annually. Mr. Mannine's employment agreement may be terminated, and he is entitled to certain payments upon such termination, as follows: · if we should terminate Mr. Mannine’s employment without “cause” or if he should resign for “good reason" or if a “change of control” occurs, we are obligated to pay him a lump-sum severance payment equal to the sum of three months’ base salary, plus one month for every year he was employed and 50% of three years annual bonus (based on the prior year’s compensation); · if Mr. Mannine’s employment is terminated as a result of his death or disability, he is entitled to receive his base salary and a pro-rata annual bonus, if any, based on the year during which such termination is effective; or · if we should terminate Mr. Mannine for “cause,” or if he voluntarily terminates the agreement, he is entitled to receive his base salary only through the date of termination, and he is not be entitled to any other compensation for the calendar year during which the termination occurs or any subsequent calendar period, including, but not limited to, any annual bonus, if any, that has not already been paid. The employment agreement with Mr. Mannine contains customary confidentiality, non-compete and indemnification clauses. On September 21, 2020, Mr. Mannine voluntarily agreed to cancel the employment agreement and waive all cash due and any related accruals. The salary forgiven for the nine months ended September 30, 2020 and 2019 of $84,943 and $85,486 is treated as in-kind contribution of service and reflected as contributed capital in the financial statements (See Note 8). Commitments On March 8, 2018, we entered into an advisory agreement with a scientific advisor to provide certain services to us. Pursuant to the agreement, we issued 100,000 five year common stock warrants at an exercise price of $0.90. Such warrants vest subject to certain milestones. As of September 30, 2020 and December 31, 2019, 66,666 of these warrants have vested. We determined that the warrant had an initial fair value of $1,905. We estimated the fair value of this warrant using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.63% and an expected life of 5 years. During the three months ended September 30, 2020 and 2019, we have recorded stock-based compensation expense related to the warrants of $56 and $143, respectively, which is included in our Selling, general and administrative expense on the accompanying Statements of Operations. During the nine months ended September 30, 2020 and 2019, we have recorded stock-based compensation expense related to the warrants of $168 and $429, respectively, which is included in our Selling, general and administrative expense on the accompanying Statements of Operations. On May 21, 2018, we entered into an Amended and Restated Strategic Financing & Corporate Development Agreement with CRG which was amended and restated an earlier agreement entered into in October 2017. We have engaged this company to serve as our non-exclusive strategic financing and corporate development services provider and to render certain advice and services to us as we may reasonably request concerning equity or debt financings, strategic planning, merger and acquisition possibilities, and business development activities. The scope of services under this agreement also includes introducing us to one or more non-U.S. persons, as that term is defined in Regulation S under the Securities Act, in connection with possible debt or equity financings or potential lenders. The initial term of the agreement expired in May 2019, but pursuant to the terms of the agreement, renews automatically for one-year periods unless notice of non-renewal is provided by either party at least 30 days prior to the renewal term commencement. The agreement was renewed in May 2020. As compensation under the terms of this agreement, we agreed to pay CRG Finance AG certain fees for transactions which are consummated during the term of the agreement and for a one year period following the termination of the agreement, including: · a fee equal to 7% of the proceeds received by us plus a warrant exercisable into 7% of the shares of our common stock at the offering price of our shares for sales by us of equity or equity-linked securities to non-U.S. Persons introduced to us by CRG Finance AG; · a fee equal to 1% of the total gross cash proceeds or non-cash consideration received by us, together with a five year warrant exercisable into 1% of the securities issued or to be issued by us in a business combination with a non-U.S. person first introduced to us by CRG Finance AG; · a fee equal to 1% of consideration received by us in any debt financing not convertible into equity, including, but not limited to, a revolving credit line or credit enhancement instrument, including on an insured or guarantee basis, with a non-U.S. Person first introduced to us by CRG Finance AG; and · a fee equal to 2% of any revenue-producing contract, fee-sharing arrangement, licensing, royalty or similar agreement with a non-U.S. Person first introduced to us by CRG Finance AG. In addition to the foregoing fees, we have agreed to reimburse CRG Finance AG for its pre-approved out of pocket expenses it incurs under the terms of the agreement. The agreement contains customary confidentiality and indemnification provisions. On February 12, 2020, we entered a consulting agreement with Primoris Group Inc (“Primoris”). Primoris was issued 200,000 common shares at a fair value of $45,000 ($0.225 per share) on June 30, 2020. 100,000 shares are restricted from resale or transfer by Primoris per the consulting agreement until February 12, 2021. The consultant has an option to register 100,000 on any future registration statement. In addition to any restrictions imposed by the agreement, all the shares require an exemption for resale to the public. During the three and nine months ended September 30, 2020, we have recorded stock-based compensation of $8,250 and $28,125, respectively. As of September 30, 2020, $16,875 is recorded in prepaid expense related to the consulting agreement. Under terms of the consulting agreement, we agree to pay Primoris $8,000 per month payable in advance of the month in which services are to be rendered as a consulting fee. Contingencies In April 2016, we entered into a Promotion and Royalty Agreement (the “Agreement”) with a consultant to obtain certain promotional services from him (the “Promoter”), including the use of his name and appearance. In consideration for the services rendered by the Promoter, we agreed to use commercially reasonable efforts to promote and sell a book authored by him (the “Book”) and to pay him a percentage of the sales of the Book after deductions for all direct costs of fulfilling such sales (the “Royalty”). During the course of 2017, the Promoter initiated a series of informal claims and filed unauthorized uniform commercial code financing statements (“UCC Liens”) in several states as liens against us and certain of our officers, directors, and founders, alleging non-payment for the Royalty amounts due under the Agreement. We dispute the Promoter’s claims and have determined that any and all amounts due to the Promoter under the Agreement have been paid in full. We have succeeded in removing certain of the UCC Liens and are pursuing action to remove the remaining unauthorized UCC Liens. We do not believe that the claims of the Promoter are valid in any respect.

Concentration of Credit Risk an

Concentration of Credit Risk and Major Customers and Suppliers	9 Months Ended
	Sep. 30, 2020
Risks and Uncertainties [Abstract]
Concentration of Credit Risk and Major Customers and Suppliers	7. Concentration of Credit Risk and Major Customers and Suppliers None of our revenues are concentrated with any single customer composing 10% or more of our total revenues. We purchase our inventory of herbal/natural supplements from one supplier. While we believe that we will be able to find a secondary supplier, there could be a manufacturing delay in the transition to a new supplier and such a supply interruption would materially impact our business for some period of time.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity	8. Stockholders’ Equity Our authorized capital stock consists of 50,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of blank check preferred stock, par value $0.0001 per share. As of September 30, 2020 and December 31, 2019, there are 11,599,830 and 11,399,830 shares of common stock outstanding and there are no shares of preferred stock issued and outstanding at either date. In-kind Contribution of Service On September 21, 2020, Mr. Mannine voluntarily agreed to cancel his employment agreement and waive all cash due and any related accruals. The salary forgiven for the nine months ended September 30, 2020 and 2019 of $84,943 and $85,486 is treated as in-kind contribution of service and reflected as contributed capital in the financial statements. Consulting Agreement On February 12, 2020, we entered a consulting agreement with Primoris Group Inc (“Primoris”). Primoris was issued 200,000 common shares at a fair value of $45,000 ($0.225 per share) on June 30, 2020. 100,000 shares are restricted from resale or transfer by Primoris per the consulting agreement until February 12, 2021. The consultant has an option to register 100,000 on any future registration statement. In addition to any restrictions imposed by the agreement, all the shares require an exemption for resale to the public. During the three and nine months ended September 30, 2020, we have recorded stock-based compensation of $8,250 and $28,125, respectively. As of September 30, 2020, $16,875 is recorded in prepaid expense related to the consulting agreement. Preferred Stock Our board of directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. The rights, preferences, limitations and restrictions of different series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions and other matters. Our board of directors may authorize the issuance of preferred stock, which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our board of directors can fix limitations and restrictions, if any, upon the payment of dividends on both classes of our common stock to be effective while any shares of preferred stock are outstanding. Warrants On October 10, 2017, we entered into the Financing Agreement with CRG. In connection with the related equity financing as of December 31, 2017, CRG had earned 368,111 fully vested five-year warrants with an exercise price of $0.225. The related warrants were issued in January 2018. We determined that the warrant had an initial fair value of $34,405 and was recorded as a direct offering cost in Stockholders’ equity with a net effect of zero. We estimated the fair value of this warrant using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.2% and an expected life of 5 years. During January 2018, as part of the Private Placement more fully described in Note 4, CRG earned an additional 17,655 fully vested common stock warrants with an exercise price of $0.225. These additional warrants were issued to CRG on January 30, 2018. We determined that the warrant had an initial fair value of $1,670 and was recorded as a direct offering cost in Stockholders’ equity with a net effect of zero. We estimated the fair value of this warrant using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.51% and an expected life of 5 years. On March 8, 2018, we entered into an advisory agreement with a scientific advisor to provide certain services to us. Pursuant to the agreement, we issued 100,000 five-year common stock warrants at an exercise price of $0.90. Such warrants vest subject to certain milestones. As of September 30, 2020 and December 31, 2019, 66,666 of these warrants have vested. We determined that the warrant had an initial fair value of $1,905. We estimated the fair value of this warrant using the Black- Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.63% and an expected life of 5 years. During the three months ended September 30, 2020 and 2019, we have recorded stock-based compensation expense of $56 and $143, respectively, which is included in our Selling, general and administrative expense on the accompanying Statements of Operations. During the nine months ended September 30, 2020 and 2019, we have recorded stock-based compensation expense of $168 and $429, respectively, which is included in our Selling, general and administrative expense on the accompanying Statements of Operations. The following table summarizes information about the warrants earned and outstanding as of September 30, 2020 and December 31, 2019: Weighted Average Exercise Warrants Price Outstanding as of December 31, 2019 485,766 $ 0.364 Granted — — Exercised — — Forfeited — — Expired — — Outstanding as of September 30,2020 485,766 $ 0.364 Exercisable as of September 30,2020 452,432 $ 0.324 As of September 30, 2020 Warrants Outstanding Warrants Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $0.225 - $0.90 485,766 2.87 $ 0.364 452,432 $ 0.324

Stock Option Plan

Stock Option Plan	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock Option Plan	9. Stock Option Plan In December 2017 our board of directors adopted our 2017 Equity Incentive Plan, or the “2017 Plan.” Our stockholders ratified the 2017 Plan in December 2017. The purpose of the 2017 Plan is to encourage ownership in our company by our officers, directors, employees and consultants, and to incentivize and align the interests of the plan participants with the interests of our stockholders. We have reserved 1,100,000 shares of our common stock for issuance under the 2017 Plan. Grants pursuant to the 2017 Plan may be: i) incentive stock options; ii) non-statutory stock options; iii) stock awards, including shares of our common stock and stock units; and iv) stock appreciation rights. The board of directors or a committee of the board of directors administers the 2017 Plan. Presently, the 2017 Plan is administered by our board of directors. The term of each plan option and the manner in which it may be exercised is determined by the board of directors or a committee of the board of directors, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant. The terms of grants or any other type of award under the plan are determined by the board of directors or committee of the board of directors at the time of grant. The 2017 Plan provides that the maximum value of any award during any calendar year cannot exceed $1,000,000. Any option granted under the plan must provide for an exercise price of not less than 100% of the fair market value of the underlying shares on the date of grant, but the exercise price of any ISO granted under the 2017 Plan to an eligible employee owning more than 10% of our outstanding common stock must not be less than 110% of fair market value on the date of the grant. The 2017 Plan further provides that with respect to ISOs the aggregate fair market value of the common stock underlying the options which are exercisable by any plan participant during any calendar year cannot exceed $100,000. Option awards may provide for the exercise by means of cash, consideration received by us under a broker-assisted sale and remittance program, cashless exercise, any other consideration legally permitted, or a combination of the foregoing. The 2017 Plan administrator may also determine the method of payment of the exercise price at the time the option is being exercised. Grants under the 2017 Plan are not transferrable. Generally, options which are exercisable at the date of the plan participant’s termination from our employment or severance of the relationship with our company must be exercised within three months of the termination date; the plan administrator may extend the exercise period of the option for a separated plan participant providing that the extended date does not go beyond the original expiration date of the option. Similarly, generally options which are exercisable at the date of the plan participant’s disability or death must be exercised within six months of the termination date in the event of the disability of the plan participant or 12 months following the plan participant’s death. In our discretion, any outstanding options held by a plan participant terminated for cause may be immediately cancelled. In the event there is a “change in control” of our company as defined in the 2017 Plan, as determined by the board of directors or the committee, we may in our discretion: i) provide for the assumption or substitution of, or adjustment (including to the number and type of shares and exercise or purchase price applicable) to, each outstanding award; ii) accelerate the vesting of options and terminate any restrictions on stock awards; and/or iii) provide for termination of awards as a result of the change in control on such terms and conditions as it deems appropriate, including providing for the cancellation of awards for a cash or other payment to the participant. The number of shares of our common stock underlying any outstanding but unexercised option and the exercise price of that option will be proportionally adjusted in the event of a stock split, stock combinations, dividends, and similar corporate events. On June 14, 2018, pursuant to the employment agreement with Mr. Mannine, more fully described in Note 6, we issued 100,000 stock options with an exercise price of $0.225. Such options fully vested upon the effectiveness of a registration statement on Form S-1. We determined that the options had an initial fair value of $13,221. We estimated the fair value of these options using the Black-Scholes option pricing model, based on the following assumptions: the recent cash offering price of $0.225 as the estimated fair value of the underlying common stock at the valuation measurement date; no dividend yield for all of the years; expected volatility of 45%; risk-free interest rate of 2.2% and an expected life of 10 years. We amortized the fair value over the period from their issuance on June 14, 2018 through December 7, 2018, the date on which the registration statement was declared effective. No stock option expense was recorded during the nine months ended September 30, 2020 and 2019. The following table summarizes information about stock options outstanding and exercisable as of as of September 30, 2020 and December 31, 2019: Weighted Average Exercise Options Price Outstanding as of December 31, 2019 100,000 $ 0.225 Granted — — Exercised — — Forfeited — — Expired — — Outstanding as of September 30, 2020 100,000 $ 0.225 Exercisable as of September 30, 2020 100,000 $ 0.225 Options available for future grant, end of year 1,000,000 As of September 30, 2020 Options Outstanding Options Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $0.225 100,000 8.69 $ 0.225 100,000 $ 0.225

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Event	10.Subsequent Events On October 27, 2020, the Company executed a note payable to an individual in the amount of $10,000, interest accrues at 5% per annum, unsecured, and due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Accounting Principles	Accounting Principles The accompanying unaudited condensed financial statements (the “Financial Statements”) of Vynleads, Inc. (the “Company,” “we,” “us” or “our”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and, therefore, do not include all information and footnotes required by GAAP for complete financial statements. In our opinion, the Financial Statements contain all adjustments of a normal recurring nature necessary to present fairly our financial position as of September 30, 2020 and the results of our operations and cash flows for the nine months ended September 30, 2020 and 2019. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the full 2020 fiscal year. The Financial Statements should be read in conjunction with the audited financial statements for the Company and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “Form 10-K”).
Use of Accounting Estimates	Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that judgement is involved in determining the valuation of our reserve for refunds, our holdback reserve, the fair value-based measurement of stock-based compensation, accruals and the estimated useful life of intangible assets. We evaluate our estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the Financial Statements.
Cash	Cash Cash includes cash on hand, is deposited at one area bank and may exceed federally insured limits at times. We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The carrying amounts reported in the balance sheets for cash and cash equivalents approximate their fair value.
Holdback Receivable	Holdback Receivable Holdback receivable includes a merchant holdback net of a reserve for refunds, which reserve is $513 and $3,111 as of September 30, 2020 and December 31, 2019, respectively.
Revenue Recognition	Revenue Recognition The Company accounts for revenue in accordance with Topic 606. Revenues are recognized when the Company satisfies a performance obligation by transferring control of the promised goods or services to our customers at a point in time, in an amount specified in the contract with our customer and that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company also assesses our customer’s ability and intention to pay, which is based on a variety of factors including our customer’s historical payment experience and financial condition. We generate revenues primarily from (i) internet content subscriptions and (ii) sales of nutritional supplements. Revenues are recognized upon the acceptance of subscription membership or shipment of nutritional supplements, provided that an order has been received or a contract executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved, and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Our percentages of revenue by type for the three and nine months ended September 30, 2020 and 2019 are as follows: Three months ended Nine months ended September 30, September 30, (Unaudited) (Unaudited) 2020 2019 2020 2019 Internet content subscriptions 10.8 % 51.6 % 7.7 % 53.6 % Nutritional supplements 89.3 % 48.4 % 92.3 % 46.4 %
Shipping and Handling Costs	Shipping and Handling Costs We include shipping and handling fees billed to customers as revenue and shipping and handling costs for shipments to customers as cost of revenue.
Advertising Costs	Advertising Costs Advertising costs for the three months ended September 30, 2020 and 2019 were $71 and $114,316, respectively. Advertising costs for the nine months ended September 30, 2020 and 2019 were $1,885 and $214,776, respectively. Advertising costs are expensed as incurred or at the first time the advertising activity takes place.
Loss Per Share	Loss Per Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income (loss) that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were excluded from the diluted loss per share calculations because the effect would be antidilutive or the options and warrants exercise prices were greater than the average market price of the common shares, were 585,766 shares for the nine months ended September 30, 2020 and 2019.
Income Taxes	Income Taxes The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. We account for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. We evaluate this tax position on a quarterly basis. We also accrue for potential interest and penalties, if applicable, related to unrecognized tax benefits in income tax expense.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation is measured at the grant date based on the estimated fair value of the award and is recognized as an expense over the requisite service period. The valuation of employee stock options is an inherently subjective process, since market values are generally not available for long-term, non-transferable employee stock options. Accordingly, the Black-Scholes option pricing model is utilized to derive an estimated fair value. The Black-Scholes pricing model requires the consideration of the following six variables for purposes of estimating fair value: · the stock option exercise price; · the expected term of the option; · the grant date price of our common stock, which is issuable upon exercise of the option; · the expected volatility of our common stock; · the expected dividends on our common stock (we do not anticipate paying dividends in the foreseeable future); and · the risk-free interest rate for the expected option term. Expected Dividends. Expected Volatility. Risk-Free Interest Rate. Expected Term. Stock Option Exercise Price and Grant Date Price of Common Stock. We are required to estimate the level of award forfeitures expected to occur and record compensation expense only for those awards that are ultimately expected to vest. This requirement applies to all awards that are not yet vested. Due to the limited number of unvested options outstanding, the majority of which are held by executives and members of our Board of Directors, we have estimated a zero forfeiture rate. We will revisit this assumption periodically and as changes in the composition of the option pool dictate.
Fair Value of Financial Instruments	Fair Value of Financial Instruments We follow Accounting Standards Codification 820-10 (“ASC 820-10”), “Fair Value Measurements and Disclosures,” for fair value measurements. ASC 820-10 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value, which focuses on an exit price, which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard also prioritizes, within the measurement of fair value, the use of market-based information over entity specific information and establishes a three-level hierarchy for fair value measurement based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. The hierarchy established under ASC 820-10 gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820-10 are described below: Level 1 - Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. As required by ASC 820-10, we do not adjust the quoted price for these investments, even in situations where we hold a large position and a sale could reasonably impact the quoted price. Level 2 - Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to these investments. Level 3 - Pricing inputs are unobservable for the investment, that is, inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Level 3 includes investments that are supported by little or no market activity. The carrying amounts of our cash, holdback receivable, prepaid expenses, accounts payable and accrued expenses approximate their fair values due to their short-term maturities as of September 30, 2020 and December 31, 2019.
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have evaluated all issued but not yet effective accounting pronouncements and determined that, other than the following, they are either immaterial or not relevant to us. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 provide for simplified accounting to several income tax situations and removal of certain accounting exceptions. The ASU is effective for annual reporting periods beginning after December 15, 2020, including interim periods within those periods. We do not expect the impact of the adoption of ASU 2019-12 to have a material effect on the Company's results of operations, cash flows or financial condition.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Percentage of Revenue by Type	Our percentages of revenue by type for the three and nine months ended September 30, 2020 and 2019 are as follows: Three months ended Nine months ended September 30, September 30, (Unaudited) (Unaudited) 2020 2019 2020 2019 Internet content subscriptions 10.8 % 51.6 % 7.7 % 53.6 % Nutritional supplements 89.3 % 48.4 % 92.3 % 46.4 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Warrants Earned and Outstanding	The following table summarizes information about the warrants earned and outstanding as of September 30, 2020 and December 31, 2019: Weighted Average Exercise Warrants Price Outstanding as of December 31, 2019 485,766 $ 0.364 Granted — — Exercised — — Forfeited — — Expired — — Outstanding as of September 30,2020 485,766 $ 0.364 Exercisable as of September 30,2020 452,432 $ 0.324
Warrants Outstanding and Exercisable by Range of Exercise Price	As of September 30, 2020 Warrants Outstanding Warrants Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $0.225 - $0.90 485,766 2.87 $ 0.364 452,432 $ 0.324

Stock Option Plan (Tables)

Stock Option Plan (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Summary of Information Regarding about Stock Options Outstanding and Exercisable	The following table summarizes information about stock options outstanding and exercisable as of as of September 30, 2020 and December 31, 2019: Weighted Average Exercise Options Price Outstanding as of December 31, 2019 100,000 $ 0.225 Granted — — Exercised — — Forfeited — — Expired — — Outstanding as of September 30, 2020 100,000 $ 0.225 Exercisable as of September 30, 2020 100,000 $ 0.225 Options available for future grant, end of year 1,000,000
Options Outstanding by Exercise Price Range	As of September 30, 2020 Options Outstanding Options Exercisable Remaining Average Weighted Weighted Range of Number Contractual Average Number Average Exercise Price Outstanding Life (In Years) Exercise Price Exercisable Exercise Price $0.225 100,000 8.69 $ 0.225 100,000 $ 0.225

Going Concern (Details)

Going Concern (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Going Concern
Net loss	$ 95,703	$ 113,356	$ 70,512	$ 83,419	$ 62,533	$ 72,844	$ 279,571	$ 218,796
Accumulated deficit	1,615,638						1,615,638		$ 1,336,067
Working capital deficits	274,896						274,896
Holdback Receivable from merchant, net of reserve for refunds	$ 30,269						$ 30,269		$ 45,284

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Accounting Policies [Abstract]
Refunds	$ 513		$ 513		$ 3,111
Advertising	$ 71	$ 114,316	$ 1,885	$ 214,776
Potentially dilutive shares			585,766	585,766

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Percentage of Revenue by Type) (Details) - Revenue [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Internet Content Subscriptions [Member]
Product Information [Line Items]
Percentage of revenues	10.80%	51.60%	7.70%	53.60%
Nutritional Supplements [Member]
Product Information [Line Items]
Percentage of revenues	89.30%	48.40%	92.30%	46.40%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Jun. 14, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Related Party Transaction [Line Items]
Options issued
Exercise price
Capital contribution from CEO's salary				$ 84,943	$ 85,486
Mr. Mannine [Member]
Related Party Transaction [Line Items]
Options issued	100,000
Exercise price	$ 0.225
Expected term	10 years
Mr. Bezusov [Member]
Related Party Transaction [Line Items]
Consulting fees		$ 0	$ 0	$ 2,000	$ 0

Notes Payable (Details)

Notes Payable (Details) - USD ($)	May 14, 2020	May 05, 2020	Nov. 18, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Other income						$ 2,000
Note Payable One [Member]
Note payable			$ 50,000
Interest rate			5.00%
Term			due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Accrued interest				894		894		$ 295
Interest paid	$ 1,250
Note Payable Two [Member]
Note payable			$ 25,000
Interest rate			5.00%
Term			due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first.
Accrued interest				$ 1,072		$ 1,072		$ 140
PPP Loan [Member]
Note payable		$ 27,000
Interest rate		1.00%
Term		payable monthly commencing on October 20, 2020. The loan is forgivable if the proceeds are used for eligible purposes. The Company intends to use the entire loan amount for qualifying expenses.

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2020	Feb. 12, 2020	Jun. 14, 2018	Mar. 08, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Other Commitments [Line Items]
Options issued
Exercise price
Capital contribution from CEO's salary							$ 84,943	$ 85,486
Stock-based compensation							28,293	429
Prepaid expense					$ 20,206		$ 20,206		$ 3,081
Scientific Advisor [Member] | Warrant [Member]
Other Commitments [Line Items]
Issued				100,000
Term				P5Y
Warrants exercise price				$ 0.90
Vested							66,666		66,666
Fair value				$ 1,905
Offering price				$ 0.225
Volatility				45.00%
Risk free interest rate				2.63%
Expected life				5 years
Stock-based compensation					56	$ 143	$ 168	429
Primoris Group Inc [Member]
Other Commitments [Line Items]
Issued		200,000
Fair value	$ 45,000
Shares restricted		100,000
Offering price		$ 0.225
Stock-based compensation					8,250		28,125
Prepaid expense					16,875		16,875
Monthly payable					$ 8,000		8,000
Mr. Mannine [Member]
Other Commitments [Line Items]
Annual base salary			$ 130,000
Options issued			100,000
Exercise price			$ 0.225
Volatility			45.00%
Risk free interest rate			2.20%
Expected life			10 years
Stock-based compensation							$ 0	$ 0

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Jun. 30, 2020	Feb. 12, 2020	Mar. 08, 2018	Oct. 10, 2017	Jan. 31, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Class of Stock [Line Items]
Preferred stock, par value						$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares authorized						5,000,000		5,000,000		5,000,000
Preferred stock, share issued						0		0		0
Preferred stock, shares outstanding						0		0		0
Common stock, par value						$ 0.0001		$ 0.0001		$ 0.0001
Common stock, shares authorized						50,000,000		50,000,000		50,000,000
Common stock, shares issued						11,599,830		11,599,830		11,399,830
Common stock, shares outstanding						11,599,830		11,599,830		11,399,830
Capital contribution from CEO's salary								$ 84,943	$ 85,486
Prepaid						$ 20,206		20,206		$ 3,081
Stock-based compensation								$ 28,293	429
CRG [Member] | Warrant [Member]
Class of Stock [Line Items]
Issued				368,111	17,655
Term				P5Y
Exercise price				$ 0.225	$ 0.225
Fair value				$ 34,405	$ 1,670
Offering price				$ 0.225	$ 0.225
Volatility				45.00%	45.00%
Risk free interest rate				2.20%	2.51%
Expected life				5 years	5 years
Scientific Advisor [Member] | Warrant [Member]
Class of Stock [Line Items]
Issued			100,000
Term			P5Y
Exercise price			$ 0.90
Vested								66,666		66,666
Fair value			$ 1,905
Offering price			$ 0.225
Volatility			45.00%
Risk free interest rate			2.63%
Expected life			5 years
Stock-based compensation						56	$ 143	$ 168	$ 429
Primoris Group Inc [Member]
Class of Stock [Line Items]
Prepaid						16,875		16,875
Shares restricted		100,000
Issued		200,000
Fair value	$ 45,000
Offering price		$ 0.225
Stock-based compensation						$ 8,250		$ 28,125

Stockholders' Equity (Informati

Stockholders' Equity (Information About Warrants Earned and Outstanding) (Details) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Outstanding, beginning of period	485,766	485,766
Granted
Exercised
Forfeited
Expired
Outstanding, end of period	485,766	485,766
Exercisable, end of period	452,432	452,432
Outstanding, beginning of period	$ 0.364	$ 0.364
Granted
Exercised
Forfeited
Expired
Outstanding, end of period	0.364	0.364
Exercisable, end of period	$ 0.324	$ 0.324

Stockholders' Equity (Warrants

Stockholders' Equity (Warrants Outstanding by Price Range) (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Class of Warrant or Right [Line Items]
Range of exercise price, lower limit	$ 0.225
Range of exercise price, upper limit	$ 0.90
Number outstanding | shares	485,766
Remaining Average Contractual Life	2 years 10 months 14 days
Weighted Average Exercise Price, Outstanding	$ 0.364
Number exercisable | shares	452,432
Weighted average exercise price, exercisable	$ 0.324

Stock Option Plan (Details)

Stock Option Plan (Details) - USD ($)	Jun. 14, 2018	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total awards reserved		1,100,000
Options issued
Exercise price
Stock-based compensation		$ 28,293	$ 429
Mr. Mannine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options issued	100,000
Exercise price	$ 0.225
Options fair value	$ 13,221
Expected volatility	45.00%
Risk free rate	2.20%
Expected term	10 years
Stock-based compensation		$ 0	$ 0

Stock Option Plan (Stock Option

Stock Option Plan (Stock Options Outstanding) (Details) - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Outstanding, beginning of period	100,000	100,000	100,000
Granted
Exercised
Forfeited
Expired
Outstanding, end of period	100,000		100,000
Exercisable, end of period	100,000		100,000
Options available for future grant, end of period	1,000,000		1,000,000
Outstanding, beginning of period	$ 0.225	$ 0.225	$ 0.225
Granted
Exercised
Forfeited
Expired
Outstanding, end of period	0.225		0.225
Exercisable	$ 0.225		$ 0.225

Stock Option Plan (Stock Opti_2

Stock Option Plan (Stock Options Outstanding by Exercise Price) (Details)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Payment Arrangement [Abstract]
Range of Exercise Price, lower	$ 0.225
Range of Exercise Price, upper	$ 0.225
Number Outstanding | shares	100,000
Remaining Average Contractual Life	8 years 8 months 9 days
Weighted Average Exercise Price	$ 0.225
Number Exercisable | shares	100,000
Exercisable Weighted Average Exercise Price	$ 0.225

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member]	Oct. 27, 2020USD ($)
Note payable	$ 10,000
Interest rate	5.00%
Term	due after six months of execution, or the date in which the Company secures one million dollars in total investment capital, whichever occurs first